Moreover, the 36-month beta value for TOI is 0.39. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TOI is 36.80M and currently, short sellers hold a 0.88% of that float. On February 21, 2025, TOI’s average trading volume was 2.06M shares.
TOI) stock’s latest price update
The stock of Oncology Institute Inc (NASDAQ: TOI) has decreased by -6.89 when compared to last closing price of 0.96.Despite this, the company has seen a loss of -5.68% in its stock price over the last five trading days. globenewswire.com reported 2025-02-11 that TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) — Topicus.com Inc. (TSXV:TOI) announced today it intends to release its fourth quarter results on February 26, 2025.
TOI’s Market Performance
TOI’s stock has fallen by -5.68% in the past week, with a monthly rise of 49.41% and a quarterly rise of 396.61%. The volatility ratio for the week is 10.77% while the volatility levels for the last 30 days are 18.03% for Oncology Institute Inc The simple moving average for the past 20 days is 0.32% for TOI’s stock, with a 100.96% simple moving average for the past 200 days.
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with Jefferies repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to Jefferies is $2.50 based on the research report published on February 26, 2024 of the previous year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see TOI reach a price target of $7. The rating they have provided for TOI stocks is “Buy” according to the report published on September 14th, 2022.
Jefferies gave a rating of “Buy” to TOI, setting the target price at $10 in the report published on August 15th of the previous year.
TOI Trading at 65.24% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.43% of loss for the given period.
Volatility was left at 18.03%, however, over the last 30 days, the volatility rate increased by 10.77%, as shares surge +27.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +360.77% upper at present.
During the last 5 trading sessions, TOI fell by -5.68%, which changed the moving average for the period of 200-days by -22.94% in comparison to the 20-day moving average, which settled at $0.8910. In addition, Oncology Institute Inc saw 189.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TOI starting from Hively Brad, who purchase 250,000 shares at the price of $0.17 back on Nov 26 ’24. After this action, Hively Brad now owns 616,753 shares of Oncology Institute Inc, valued at $42,500 using the latest closing price.
Hively Brad, the Director of Oncology Institute Inc, purchase 50,000 shares at $0.15 during a trade that took place back on Dec 02 ’24, which means that Hively Brad is holding 666,753 shares at $7,500 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.13 for the gross margin
The net margin for Oncology Institute Inc stands at -0.17. The total capital return value is set at -0.48. Equity return is now at value -131.66, with -28.92 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 0.89 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 7.94. The interest coverage ratio of the stock is -7.68.
Currently, EBITDA for the company is -70.45 million with net debt to EBITDA at -1.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.38. The receivables turnover for the company is 6.91for trailing twelve months and the total asset turnover is 2.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
To wrap up, the performance of Oncology Institute Inc (TOI) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
